Alector (ALEC) Azione Prezzo
Alector Prezzo
Negli ultimi 9 anni Alector ha aumentato il fatturato del 54,6% all'anno, raggiungendo 21,05 Mio. USD. Per Alector, il margine netto del -679,2% risulta in calo rispetto al -13,5% di alcuni anni fa. Il target di prezzo di consenso a 12 mesi per Alector è 2,00 USD, circa il 8,7% sopra il prezzo attuale di mercato. Su 14 analisti, 8 valutano il titolo come acquisto — nel complesso un consenso Acquistare.
Alector Prezzo delle azioni
Accedi a questi dati tramite l’API Eulerpool
100.000 richieste/mese gratis · nessuna carta di credito
Alector Azione e analisi azionaria
Domande frequenti sull'azione Alector
Alector Inc's business model focuses on utilizing its expertise in immunology and neurodegenerative diseases to develop innovative therapies. The company aims to harness the power of the immune system to target dysfunctional pathways and address the underlying causes of diseases like Alzheimer's and Parkinson's. Alector Inc leverages its proprietary immuno-neurology platform to identify potential therapeutic targets and develop antibodies that modulate the immune system's response. Through strategic collaborations and clinical trials, Alector Inc aims to advance transformative treatments and improve the lives of patients suffering from neurodegenerative disorders.
Alector Inc is primarily active in the biotechnology industry.
Alector Inc's main competitors in the market include Biogen Inc, Eli Lilly and Company, and Denali Therapeutics Inc.
Alector Inc is a biotechnology company founded in 2013 and is headquartered in South San Francisco, California. The company was established with a mission to develop innovative therapies to combat neurodegenerative diseases, including Alzheimer's disease and frontotemporal dementia. Alector focuses on harnessing the power of the immune system to target and eliminate disease-causing proteins, with the aim of slowing down or halting disease progression. Over the years, Alector has made significant advancements in its research and development, forging strategic partnerships and collaborations to drive the development of potential breakthrough treatments. Alector Inc remains committed to making a positive impact on patients' lives by addressing the urgent needs in neurological diseases.
Alector Inc has achieved significant milestones in its journey. The company has successfully advanced its proprietary immuno-neurology platform, focusing on developing transformative therapies for neurodegenerative diseases. A key achievement includes progressing its lead product candidates, AL002 and AL003, into clinical trials, demonstrating promising results and potential therapeutic benefits. Alector Inc has also secured strategic collaborations and partnerships with renowned pharmaceutical companies, enabling further research and development opportunities. These milestones highlight the company's dedication to innovative solutions in addressing critical unmet needs in the field of neurodegenerative disorders. Alector Inc's continued progress positions it as a leading player in the biotechnology industry, with a strong focus on improving patient outcomes.
Alector Inc is primarily present in the United States.
Alector Inc represents values of innovation, collaboration, and dedication to finding novel therapeutic treatments for neurodegenerative disorders. With a mission to improve the lives of patients, the company focuses on developing immune-modulatory therapies to target the root causes of diseases like Alzheimer's and Parkinson's. Alector Inc's corporate philosophy prioritizes scientific excellence, cutting-edge research, and a patient-centric approach. By harnessing the power of the immune system, the company aims to transform the treatment landscape and provide hope to individuals and families affected by neurodegenerative diseases. Alector Inc's commitment to scientific advancements and addressing unmet medical needs drives its mission to make a lasting impact in the field.
Gli analisti fissano attualmente un prezzo obiettivo medio di 2,00 USD per l’azione Alector (mediana: 2,00 USD), pari a +8,7 % rispetto all’ultimo prezzo. Il consenso si basa su 14 giudizi di analisti.
14 analisti valutano attualmente l’azione Alector: 8 raccomandano l’acquisto, 4 la tenuta e 2 la vendita. Per il 2026 gli analisti si aspettano per Alector ricavi pari a 23,22 Mio. USD e un utile per azione di -0,76 USD.
Convertita al tasso di cambio attuale, l’azione Alector quota 1,64 EUR (1,84 USD).
L’azione Alector (ALEC) è quotata su 4 borse, tra cui: NASDAQ (ALEC), Frankfurt (0Z2.F), München (0Z2.MU), Düsseldorf (0Z2.DU).
Alector Inc is an innovative biotechnology company specializing in the research, development, and marketing of drugs to combat neurodegenerative diseases such as Alzheimer's and Parkinson's. The company was founded in 2013 by four leading experts in the field of neurobiology and is headquartered in South San Francisco, California, USA. Alector's business model is focused on developing groundbreaking therapies and drugs in the field of neurodegeneration. The company has several divisions, including a research team, clinical development departments, and a marketing and sales department. Alector's research team is involved in the identification and characterization of target proteins and mechanisms that are involved in the onset and progression of neurodegenerative diseases. The company uses an innovative, data-driven approach to understand the biological basis of these diseases and develop new targeted therapeutics. Alectron has developed a proprietary platform technology called "Immune Modulation Technology (IMT)", which utilizes the immune system in a unique way. IMT aims to modulate the activity of certain immune cells, called monocytes and macrophages. These cells are known to have the ability to eliminate pathogenic germs and abnormal proteins that can trigger neurodegenerative processes. However, in some cases, monocytes and macrophages themselves can produce harmful molecules and impair the body's defense mechanism against neurodegenerative diseases. Alector's approach is to selectively manipulate the activity of these cells and help them unleash their protective effect against neuropsychiatric disorders. Alector has conducted several clinical studies, including Phase 1 and Phase 2 studies with antibody products targeting neurodegenerative diseases. Currently, Alector is focusing on two core technologies. One is the so-called "Progranulin Receptor" (PGRN), which is attributed with significant therapeutic potential. The other is a model system called MET, which is also associated with neurodegenerative diseases. The company has also entered into several strategic partnerships with renowned pharmaceutical and technology companies to strengthen its portfolio of neurodegenerative therapeutics and its market position. These partnerships include collaborations with Biogen Inc. and AbbVie Inc. In summary, Alector aims to achieve a leading position in the market for neuropsychiatric diseases and deliver groundbreaking therapies for patients suffering from these often deadly and highly threatening diseases. It is based on the belief that an innovative approach combined with advanced technology and strategic partnerships offers the opportunity to have a positive impact on society and the health of millions of people worldwide.
Il attesa fatturato di Alector ammonta a 23,22 Mio. USD. Questo dato si basa sui dati finanziari attuali e riflette lo sviluppo commerciale dell'azienda.
Il attesa profitto di Alector ammonta a -78,12 Mio. USD. L'utile netto riflette la redditività dell'azienda dopo la deduzione di tutti i costi.
Il rapporto prezzo/utili (P/E) di Alector è attualmente -2,43. Il rapporto P/E confronta il prezzo attuale dell'azione con l'utile per azione e aiuta gli investitori a valutare la valutazione dell'azione Alector.
Il rapporto prezzo/fatturato (P/S) di Alector è attualmente 8,16. Il rapporto P/S confronta la capitalizzazione di mercato con il fatturato annuo e funge da indicatore di valutazione dell'azione Alector.
Il Quality Score AlleAktien per Alector è 2/10.
L'ISIN di Alector è US0144421072. L'ISIN (International Securities Identification Number) è un codice identificativo univoco a livello mondiale per i titoli.
Il WKN di Alector è A2PCBM. Il WKN (Wertpapierkennnummer) è un codice identificativo tedesco a sei cifre per i titoli.
Il ticker di Alector è ALEC. Con questo simbolo di borsa vengono negoziate le azioni Alector in borsa.
Azione Alector
Gruppo di pari di Alector
Alector Ticker
Alector FIGI
Altre metriche e analisi di Alector in Deep Dive.
La nostra analisi azionaria dell'azione Alector include importanti indicatori finanziari come il fatturato, l'utile, il P/E, il P/S, l'EBIT, oltre a informazioni sul dividendo. Inoltre, esaminiamo aspetti come le azioni, la capitalizzazione di mercato, il debito, il patrimonio netto e le passività di Alector. Se state cercando informazioni più dettagliate su questi temi, sulle nostre sottopagine offriamo analisi approfondite: